| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.18 | 1e-05 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-05 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.34 | 1e-05 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-05 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.24 | 2e-05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.2 | 2e-05 |